Insulin and atherosclerosis: How are they related?

Diabetes and Metabolism

Volumn 39, Issue 2, 2013, Pages 111-117

  Monnier, L ^a   Hanefeld, M ^b   Schnell, O ^c   Colette, C ^a   Owens, D ^d  

^a UNIV MONTPELLIER   (France)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerosis; Insulin

Indexed keywords

GLUCOSE; INSULIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PLEIOTROPY; REVIEW;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARRIER PROTEINS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPID PEROXIDATION; MALE; MATRIX METALLOPROTEINASES; NF-KAPPA B; NUCLEAR PROTEINS; OXIDATIVE STRESS; TRIGLYCERIDES;

EID: 84875937923     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.02.001     Document Type: Review

References (40)

1. Monnier L., Colette C., Owens D. The glycaemic triumvirate and diabetic complications: is the whole greater than the sum of its components parts?. Diabetes Res Clin Pract 2012, 95:303-311.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
4. Holman R.R., Farmer A.J., Davies M.J., Levy J.C., Darbyshire J.L., Keenan J.F., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736-1747.
5. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
6. Wellen K.E., Hotamisligil G.S. Inflammation, stress and diabetes. J Clin Invest 2005, 115:111-119.
7. Stumvoll M., Jacob S. Multiple sites of insulin resistance: muscle, liver and adipose tissue. Exp Clin Endocrinol Diabetes 1999, 107:107-110.
8. Le Marchand-Brustel Y. Molecular mechanisms of insulin action in normal and insulin-resistant states. Exp Clin Endocrinol Diabetes 1999, 107:126-132.
9. De Fronzo R.A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
10. Rensing K.L., Reuwer A.Q., Arsenault B.J., von der Thüsen J.H., Hoekstra J.B.L., Kastelein J.J.P., et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much or a good thing?. Diabetes Obes Metab 2011, 13:1073-1087.
11. Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009, 53(Suppl. S):S14-S20.
12. Dandona P., Ghanim H., Mohanty P., Chaudhuri A. The metabolic syndrome: linking oxidative stress and inflammation to obesity, type 2 diabetes and the syndrome. Drug Dev Res 2006, 67:619-626.
13. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
14. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
15. The Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
16. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
18. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
19. Monnier L., Colette C., Mas E., Michel F., Cristol J.P., Boegner C., et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010, 53:562-571.
20. Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Effect of hyperglycaemia and insulin in acute coronary syndromes. Am J Cardiol 2007, 99:12H-18H.
21. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycaemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
22. Ceriello A. Postprandial hyperglycaemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7.
23. Ahima R.S. Connecting obesity, aging and diabetes. Nat Med 2009, 15:996-997.
24. Schisano B., Tripathi G., McGee K., McTernan P.G., Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011, 54:1219-1226.
25. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
26. Malmberg K., Rydén L., Efendic S., Herlitz J., Nicol P., Waldenström A., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1year. J Am Coll Cardiol 1995, 20:57-65.
27. Malmberg K., Rydén L., Wedel H., Birkeland K., Bootsma A., Dickstein K., et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26:650-661.
28. Krinsley J. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008, 36:3008-3013.
29. Raz I., Wilson P.W.F., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32:381-386.
30. Siegelaar S.E., Kerr L., Jacober S.J., Devries J.M. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011, 34:855-857.
31. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Eng J Med 2010, 362:1463-1476.
32. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
33. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
34. McCoy R.G., Van Houten H.K., Ziegenfuss J.Y., Shah N.D., Wermers R.A., Smith S.A. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012, 35:1897-1901.
35. Jandeleit-Dahm K.A.M., Gray S.P. Insulin and cardiovascular disease: biomarker or association?. Diabetologia 2012, 55:3145-3151.
36. Monnier L., Colette C., Michel F., Cristol J.P., Owens D.R. Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes Metab Res Rev 2011, 27:348-353.
37. The ORIGIN Trial Investigators Rationale, design and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycaemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008, 155:26-32.
38. The ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia. N Eng J Med 2012, 367:319-328.
39. Zoungas S., Chalmers J., Nicomiya T., Li Q., Cooper M.E., Colagiuri S., et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012, 55:636-643.
40. Monnier L., Wojtuscizyn A., Colette C., Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011, 13:813-818.